Angiotensin-Converting Enzyme Inhibitors and Cognitive Decline in Older Adults With Hypertension: Results From the Cardiovascular Health Study | Dementia and Cognitive Impairment | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Hebert  LEScherr  PABienias  JLBennett  DAEvans  DA Alzheimer disease in the US population: prevalence estimates using the 2000 census.  Arch Neurol 2003;60 (8) 1119- 1122PubMedGoogle ScholarCrossref
2.
Brookmeyer  RGray  SKawas  C Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset.  Am J Public Health 1998;88 (9) 1337- 1342PubMedGoogle ScholarCrossref
3.
Skoog  I The relationship between blood pressure and dementia: a review.  Biomed Pharmacother 1997;51 (9) 367- 375PubMedGoogle ScholarCrossref
4.
Hanon  OSeux  MLLenoir  HRigaud  ASForette  F Hypertension and dementia.  Curr Cardiol Rep 2003;5 (6) 435- 440PubMedGoogle ScholarCrossref
5.
Launer  LJRoss  GWPetrovitch  H  et al.  Midlife blood pressure and dementia: the Honolulu-Asia aging study.  Neurobiol Aging 2000;21 (1) 49- 55PubMedGoogle ScholarCrossref
6.
Guo  ZFratiglioni  LZhu  LFastbom  JWinblad  BViitanen  M Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use.  Arch Neurol 1999;56 (8) 991- 996PubMedGoogle ScholarCrossref
7.
in't Veld  BARuitenberg  AHofman  AStricker  BHBreteler  MM Antihypertensive drugs and incidence of dementia: the Rotterdam Study.  Neurobiol Aging 2001;22 (3) 407- 412PubMedGoogle ScholarCrossref
8.
Khachaturian  ASZandi  PPLyketsos  CG  et al.  Antihypertensive medication use and incident Alzheimer disease: the Cache County Study.  Arch Neurol 2006;63 (5) 686- 692PubMedGoogle ScholarCrossref
9.
Amenta  FMignini  FRabbia  FTomassoni  DVeglio  F Protective effect of anti-hypertensive treatment on cognitive function in essential hypertension: analysis of published clinical data.  J Neurol Sci 2002;203-204147- 151PubMedGoogle ScholarCrossref
10.
Forette  FSeux  MLStaessen  JA  et al. Systolic Hypertension in Europe Investigators, The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study.  Arch Intern Med 2002;162 (18) 2046- 2052PubMedGoogle ScholarCrossref
11.
Tzourio  CAnderson  CChapman  N  et al. PROGRESS Collaborative Group, Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease.  Arch Intern Med 2003;163 (9) 1069- 1075PubMedGoogle ScholarCrossref
12.
Lithell  HHansson  LSkoog  I  et al. SCOPE Study Group, The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.  J Hypertens 2003;21 (5) 875- 886PubMedGoogle ScholarCrossref
13.
McGuinness  BTodd  SPassmore  PBullock  R The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease.  Cochrane Database Syst Rev 2006; (2) CD004034PubMedGoogle Scholar
14.
Wright  JWReichert  JRDavis  CJHarding  JW Neural plasticity and the brain renin-angiotensin system.  Neurosci Biobehav Rev 2002;26 (5) 529- 552PubMedGoogle ScholarCrossref
15.
Tuppo  EEArias  HR The role of inflammation in Alzheimer's disease.  Int J Biochem Cell Biol 2005;37 (2) 289- 305PubMedGoogle ScholarCrossref
16.
Yaffe  KLindquist  KPenninx  BW  et al.  Inflammatory markers and cognition in well-functioning African-American and white elders.  Neurology 2003;61 (1) 76- 80PubMedGoogle ScholarCrossref
17.
Wyss  JMKadish  Ivan Groen  T Age-related decline in spatial learning and memory: attenuation by captopril.  Clin Exp Hypertens 2003;25 (7) 455- 474PubMedGoogle ScholarCrossref
18.
Fitzpatrick  ALKuller  LHIves  DG  et al.  Incidence and prevalence of dementia in the Cardiovascular Health Study.  J Am Geriatr Soc 2004;52 (2) 195- 204PubMedGoogle ScholarCrossref
19.
Lopez  OLKuller  LHFitzpatrick  AIves  DBecker  JTBeauchamp  N Evaluation of dementia in the cardiovascular health cognition study.  Neuroepidemiology 2003;22 (1) 1- 12PubMedGoogle ScholarCrossref
20.
Tan  JWang  JMLeenen  FH Inhibition of brain angiotensin-converting enzyme by peripheral administration of trandolapril versus lisinopril in Wistar rats.  Am J Hypertens 2005;18 (2, pt 1) 158- 164PubMedGoogle ScholarCrossref
21.
Cushman  DWWang  FLFung  WCHarvey  CMDeForrest  JM Differentiation of angiotensin-converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs.  Am J Hypertens 1989;2 (4) 294- 306PubMedGoogle Scholar
22.
Jouquey  SMathieu  MNHamon  GChevillard  C Effect of chronic treatment with trandolapril or enalapril on brain ACE activity in spontaneously hypertensive rats.  Neuropharmacology 1995;34 (12) 1689- 1692PubMedGoogle ScholarCrossref
23.
Jenkins  TAMendelsohn  FAChai  SY Angiotensin-converting enzyme modulates dopamine turnover in the striatum.  J Neurochem 1997;68 (3) 1304- 1311PubMedGoogle ScholarCrossref
24.
Gohlke  PScholkens  BHenning  RUrbach  HUnger  T Inhibition of converting enzyme in brain tissue and cerebrospinal fluid of rats following chronic oral treatment with the converting enzyme inhibitors ramipril and Hoe 288.  J Cardiovasc Pharmacol 1989;14 ((suppl 4)) S32- S36PubMedGoogle ScholarCrossref
25.
Chrysant  SGChrysant  GS Pharmacological and clinical profile of moexipril: a concise review.  J Clin Pharmacol 2004;44 (8) 827- 836PubMedGoogle ScholarCrossref
26.
Chai  SYPerich  RJackson  BMendelsohn  FAJohnston  CI Acute and chronic effects of angiotensin-converting enzyme inhibitors on tissue angiotensin-converting enzyme.  Clin Exp Pharmacol Physiol Suppl 1992;197- 12PubMedGoogle ScholarCrossref
27.
Johnston  CIFabris  BYamada  H  et al.  Comparative studies of tissue inhibition by angiotensin converting enzyme inhibitors.  J Hypertens Suppl 1989;7 (5) S11- S16PubMedGoogle ScholarCrossref
28.
Johnston  CIMendelsohn  FACubela  RBJackson  BKohzuki  MFabris  B Inhibition of angiotensin converting enzyme (ACE) in plasma and tissues: studies ex vivo after administration of ACE inhibitors.  J Hypertens Suppl 1988;6 (3) S17- S22PubMedGoogle Scholar
29.
Teng  ELChui  HC The Modified Mini-Mental State (3MS) Examination.  J Clin Psychiatry 1987;48 (8) 314- 318PubMedGoogle Scholar
30.
Lawton  MPBrody  EM Assessment of older people: self-maintaining and instrumental activities of daily living.  Gerontologist 1969;9 (3) 179- 186PubMedGoogle ScholarCrossref
31.
Radloff  LS The CES-D Scale: a self-report depression scale for research in the general population.  Appl Psychol Meas 1977;1 (3) 385- 401Google ScholarCrossref
32.
Rea  TDBreitner  JCPsaty  BM  et al.  Statin use and the risk of incident dementia: the Cardiovascular Health Study.  Arch Neurol 2005;62 (7) 1047- 1051PubMedGoogle ScholarCrossref
33.
Klein  JPMoeschberger  ML  Survival Analysis: Techniques for Censored and Truncated Data.   New York, NY Springer Publishing Co Inc1997;
34.
Ohrui  TMatsui  TYamaya  M  et al.  Angiotensin-converting enzyme inhibitors and incidence of Alzheimer's disease in Japan.  J Am Geriatr Soc 2004;52 (4) 649- 650PubMedGoogle ScholarCrossref
35.
Tedesco  MARatti  GDi Salvo  GNatale  F Does the angiotensin II receptor antagonist losartan improve cognitive function?  Drugs Aging 2002;19 (10) 723- 732PubMedGoogle ScholarCrossref
36.
Savaskan  EHock  COlivieri  G  et al.  Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia.  Neurobiol Aging 2001;22 (4) 541- 546PubMedGoogle ScholarCrossref
37.
Barnes  NMCheng  CHCostall  BNaylor  RJWilliams  TJWischik  CM Angiotensin converting enzyme density is increased in temporal cortex from patients with Alzheimer's disease.  Eur J Pharmacol 1991;200 (2-3) 289- 292PubMedGoogle ScholarCrossref
38.
Barnes  JMBarnes  NMCostall  B  et al.  Angiotensin II inhibits acetylcholine release from human temporal cortex: implications for cognition.  Brain Res 1990;507 (2) 341- 343PubMedGoogle ScholarCrossref
39.
Barnes  JMBarnes  NMCostall  BHorovitz  ZPNaylor  RJ Angiotensin II inhibits the release of [3H]acetylcholine from rat entorhinal cortex in vitro.  Brain Res 1989;491 (1) 136- 143PubMedGoogle ScholarCrossref
40.
Ruitenberg  Aden Heijer  TBakker  SL  et al.  Cerebral hypoperfusion and clinical onset of dementia: the Rotterdam Study.  Ann Neurol 2005;57 (6) 789- 794PubMedGoogle ScholarCrossref
41.
Zou  KYamaguchi  HAkatsu  H  et al.  Angiotensin-converting enzyme converts amyloid beta-protein 1-42 (Abeta(1-42)) to Abeta(1-40), and its inhibition enhances brain Abeta deposition.  J Neurosci 2007;27 (32) 8628- 8635PubMedGoogle ScholarCrossref
42.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).  JAMA 2002;288 (23) 2981- 2997PubMedGoogle ScholarCrossref
43.
Psaty  BMLumley  TFurberg  CD  et al.  Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.  JAMA 2003;289 (19) 2534- 2544PubMedGoogle ScholarCrossref
44.
Psaty  BMKoepsell  TDLin  D  et al.  Assessment and control for confounding by indication in observational studies.  J Am Geriatr Soc 1999;47 (6) 749- 754PubMedGoogle Scholar
45.
Di Bari  BMPahor  MFranse  LV  et al.  Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial.  Am J Epidemiol 2001;153 (1) 72- 78PubMedGoogle ScholarCrossref
46.
Barker  WHMullooly  JPLinton  KL Trends in hypertension prevalence, treatment, and control: in a well-defined older population.  Hypertension 1998;31 (1, pt 2) 552- 559PubMedGoogle ScholarCrossref
Original Investigation
July 13, 2009

Angiotensin-Converting Enzyme Inhibitors and Cognitive Decline in Older Adults With Hypertension: Results From the Cardiovascular Health Study

Author Affiliations

Author Affiliations: Sticht Center on Aging, Wake Forest University, Winston-Salem, North Carolina (Drs Sink, Leng, Williamson, Kritchevsky, Atkinson, Robbins, and Goff); Departments of Neurology and Psychiatry, University of California, San Francisco (Dr Yaffe); Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania (Dr Kuller); Division of Geriatric Medicine, The Johns Hopkins University, Baltimore, Maryland (Dr Yasar); and Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle (Dr Psaty).Group Information: A list of the principal investigators and institutions of the Cardiovascular Health Study can be found at http://www.chs-nhlbi.org/pi.htm.

Arch Intern Med. 2009;169(13):1195-1202. doi:10.1001/archinternmed.2009.175
Abstract

Background  Hypertension (HTN) is a risk factor for dementia, and animal studies suggest that centrally active angiotensin-converting enzyme (ACE) inhibitors (those that cross the blood-brain barrier) may protect against dementia beyond HTN control.

Methods  Participants in the Cardiovascular Health Study Cognition Substudy with treated HTN and no diagnosis of congestive heart failure (n = 1054; mean age, 75 years) were followed up for a median of 6 years to determine whether cumulative exposure to ACE inhibitors (as a class and by central activity), compared with other anti-HTN agents, was associated with a lower risk of incident dementia, cognitive decline (by Modified Mini-Mental State Examination [3MSE]), or incident disability in instrumental activities of daily living (IADLs).

Results  Among 414 participants who were exposed to ACE inhibitors and 640 who were not, there were 158 cases of incident dementia. Compared with other anti-HTN drugs, there was no association between exposure to all ACE inhibitors and risk of dementia (hazard ratio [HR], 1.01; 95% confidence interval [CI], 0.88-1.15), difference in 3MSE scores (−0.32 points per year; P = .15), or odds of disability in IADLs (odds ratio [OR], 1.06; 95% CI, 0.99-1.14). Adjusted results were similar. However, centrally active ACE inhibitors were associated with 65% less decline in 3MSE scores per year of exposure (P = .01), and noncentrally active ACE inhibitors were associated with a greater risk of incident dementia (adjusted HR, 1.20; 95% CI, 1.00-1.43 per year of exposure) and greater odds of disability in IADLs (adjusted OR, 1.16; 95% CI, 1.03-1.30 per year of exposure) compared with other anti-HTN drugs.

Conclusions  While ACE inhibitors as a class do not appear to be independently associated with dementia risk or cognitive decline in older hypertensive adults, there may be within-class differences in regard to these outcomes. These results should be confirmed with a randomized clinical trial of a centrally active ACE inhibitor in the prevention of cognitive decline and dementia.

×